PALO ALTO, Calif.--(BUSINESS WIRE)--Cromatic, a full-stack digital platform for outsourced life sciences research, today announced it has closed $5.3 million in funding. LifeX Ventures and AgFunder led the round with participation from Work Life Ventures, Not Boring Capital, FJ Labs, What If Ventures, Lux Capital, and angel investors..

加利福尼亚州帕洛阿尔托（BUSINESS WIRE）-Cromatic是外包生命科学研究的全套数字平台，今天宣布已关闭530万美元的资金。LifeX Ventures和AgFunder领导了这一轮工作，参与了Work Life Ventures，Not Boring Capital，FJ Labs，What If Ventures，Lux Capital和angel投资者。。

The demand for biotech and pharmaceutical R&D outsourcing is growing rapidly and is expected to be worth $275 billion by 2030. The explosion of biotech in the last decade has seen a doubling of the number of drug candidates under development, with many emerging biotechs outsourcing up to 90% of R&D and operating as “virtual” companies.

对生物技术和制药研发外包的需求正在迅速增长，预计到2030年将达到2750亿美元。生物技术在过去十年的爆炸式增长使正在开发的候选药物数量翻了一番，许多新兴生物技术外包高达90%的研发并作为“虚拟”公司运营。

Across the industry—from small virtual biotechs to large pharma—drug developers are managing R&D costs, addressing capacity constraints, and accessing innovation by outsourcing activities that were historically handled in-house. However, the outsourced R&D service market is highly fragmented and rife with challenges for scientists and procurement departments.

从小型虚拟生物技术公司到大型制药药物开发商，整个行业都在管理研发成本，解决能力限制问题，并通过外包历史上内部处理的活动来获取创新。然而，外包研发服务市场高度分散，充满了科学家和采购部门的挑战。

Finding the right R&D partner can take months and many projects fail due to poor communication and project management. Cromatic is on a mission to tackle these challenges..

找到合适的研发合作伙伴可能需要几个月时间，许多项目由于沟通和项目管理不善而失败。Cromatic的使命是应对这些挑战。。

Cromatic’s seamless matching platform helps biotech companies connect with vetted CROs in less than 24 hours. The platform includes a suite of software tools for communication, collaboration, project and management along with a fully integrated payment solution. In the few months since the launch of its platform, Cromatic has over $15 million in R&D budget under management and has established partnerships with leading biotech accelerators, including Nucleate, SOSV, and ValleyDAO.

Cromatic的无缝匹配平台可帮助生物技术公司在不到24小时内与经过审核的克罗斯联系。该平台包括一套用于通信，协作，项目和管理的软件工具以及完全集成的支付解决方案。自平台推出以来的几个月中，Cromatic在管理层的研发预算中拥有超过1500万美元，并与领先的生物技术加速器（包括Nucleate，SOSV和ValleyDAO）建立了合作关系。

In recognition of its rapid growth, Cromatic was spotlighted as one of the top 40 TechBio companies in Decoding Bio Snapshot 2023..

鉴于其快速增长，Cromatic被视为解码Bio Snapshot 2023的40大TechBio公司之一。。

Ann Lin, co-founder and CEO of Cromatic said, 'Outsourcing R&D is one of the most powerful ways for innovative biotech companies to get off the ground. While founders of tech giants like Apple and Google could build their products in garages with minimal resources, founders in biotech are confronted with the capital expense of lab space and equipment and the lengthy process of building the right team before they can even test their ideas.

Cromatic的联合创始人兼首席执行官安·林说，“外包研发是创新生物技术公司脱离地面的最有力方式之一。虽然苹果和谷歌等科技巨头的创始人可以在资源最少的情况下在花店里建造他们的产品，但生物技术的创始人面临着实验室空间和设备的资本支出以及在他们甚至可以测试他们的想法之前建立正确团队的漫长过程。

That’s why we are building the most powerful R&D outsourcing platform for biotechs, so that scientists will have clarity, confidence and choice when evaluating and managing their service providers. Ultimately, we want to enable biotech companies to start in garages, just like tech giants.”.

这就是为什么我们正在建立最强大的生物技术研发外包平台，以便科学家在评估和管理其服务提供商时能够清晰，自信和选择。最终，我们希望让生物技术公司能够像科技巨头一样开始在工厂工作。”。

'Our mission at Cromatic is deeply rooted in leveraging technology to reshape the landscape of biotech research,” says Anne Chen, Cromatic co-founder and CTO. “By bridging the gap between scientific innovation and efficient outsourcing, we're not only empowering scientists to bring their ideas to life but also revolutionizing the speed at which life-changing discoveries reach the world.

Cromatic联合创始人兼首席技术官安妮·陈（Anne Chen）说：“我们在Cromatic的使命深深植根于利用技术重塑生物技术研究的格局。“通过弥合科学创新与有效外包之间的差距，我们不仅赋予科学家们将自己的想法带入生活的能力，而且还彻底改变改变生活的发现到达世界的速度。

We're paving the way for a new era of agile and resource-efficient biotech development.'.

我们正在为敏捷和资源高效的生物技术开发的新时代铺平道路。

“We've seen incredible growth in the outsourced R&D market, but scientists still spend an inordinate amount of time on administrative tasks rather than value-add experimentation,' said Inaki Berenguer, Managing Partner at LifeX Ventures. 'The full stack solution—from matching, contract management, data exchange, project tracking and payments—is the right approach to accelerate and democratize the research process, bringing life-saving drugs faster to market.

“我们已经看到外包研发市场出现了令人难以置信的增长，但科学家们仍然花在行政任务上的时间而不是增值实验，”LifeX Ventures的管理合作伙伴Inaki Berenguer说。匹配，合同管理，数据交换，项目跟踪和支付的全套解决方案是加速和民主的正确方法研究过程，使救生药物更快推向市场。

Ann’s first-hand experience of the struggles to find trusted R&D partners provides a unique perspective and network within the industry. We're excited to partner with Cromatic as they continue to scale up.'.

安在寻找可信赖的研发合作伙伴方面的第一手经验为行业提供了独特的视角和网络。随着他们继续扩大规模，我们很高兴与Cromatic合作。

“The outsourced R&D landscape is a mess,” said Andrew Finkelstein, a VC at AgFunder. “It’s a patchwork of globally hard-to-find specialists, manual workflows, and custom software; and it’s driving up the cost of innovation. Cromatic is spearheading a biotech revolution by bringing outsourced R&D all under one roof with a marketplace of vetted CROs and a suite of project management tools for contracted projects.

AgFunder的VC Andrew Finkelstein说：“外包研发格局混乱。”。“这是全球难以找到的专家，手动工作流程和定制软件的拼凑品，并且正在推动创新成本.Cromatic正在率先开展生物技术革命，将所有研发外包到一个屋顶上，并设有经过审查的CRO市场和一套合同项目的项目管理工具。

From crop development and cancer therapeutics to food safety, Cromatic supports the technologies that are reshaping human and planetary health.”.

从作物开发和癌症治疗到食品安全，Cromatic支持重塑人类和行星健康的技术。”。

“Big Pharma is increasingly outsourcing innovation to the biotech sector,” said Elliot Hershberg, Biotech Partner at Not Boring. “Now, two out of three drugs that come to market began life in smaller companies. During this transition, there’s been an outpouring of R&D talent into CROs. Cromatic is harnessing this newfound capacity in a coherent platform for a new generation of nimble and capital-efficient biotech companies.

“大型制药公司越来越多地将创新外包给生物技术领域，”生物技术合作伙伴Elliot Hershberg说，并不无聊。“现在，上市的三种药物中有两种开始在小公司中生活。在这个转变过程中，研发人才大量涌入CRO。Cromatic正在利用这一新发现的能力，为新一代的灵活性和资本效率高的生物技术公司。

We anticipate that in the coming years, real research breakthroughs will happen on Cromatic’s platform.”.

我们预计未来几年，Cromatic平台将出现真正的研究突破。”。

This funding round will fast track Cromatic's product roadmap for biotechs and CROs, forge strategic partnerships and expand its team across product, engineering, sales and customer success.

这一轮资金将快速跟踪Cromatic的生物技术和CRO产品路线图，建立战略合作伙伴关系，并在产品，工程，销售和客户成功方面扩大团队。